Diabetes Research and Clinical Practice
Volume 66, Issue 1 , Pages 23-29 , October 2004

Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients

  • Mark L. Warren

      Affiliations

    • Department of Endocrinology and Metabolism, Physicians East, PA, 1850 W. Arlington Blvd., Greenville, NC 27834, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Martin J. Conway

      Affiliations

    • Lovelace Scientific Resources Inc., Albuquerque, NM, USA
    • ,
  • Leslie J. Klaff

      Affiliations

    • Rainier Clinical Research Center Inc., Renton, WA, USA
    • ,
  • Julio Rosenstock

      Affiliations

    • Dallas Diabetes and Endocrine Center, Dallas, TX, USA
    • ,
  • Elsie Allen

      Affiliations

    • Novo Nordisk Pharmaceuticals, Inc., Princeton, NJ, USA

,Revised 28 January 2004 ,Accepted 6 February 2004.

References 

  1. Brunner GA, Hirschberger S, SendLhofer G, Wutte A, Ellmerer M, Schaupp L, et al. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabet. Med. 2000;17:371–375
  2. Danne T, Aaman J, Schober E, Deiss D, Jacobsen JL, Friberg . Preprandial vs. postprandial insulin aspart treatment in type 1 diabetic children and adolescents. Diabetologia. 2001;44(Suppl. 1):A257
  3. Kang S, Brange J, Burch A, Volund A, Owens DR. Absorption kinetics and action profiles of subcutaneously administered insulin analogues (Asp B9, Blu B27, Asp B10, Asp B28) in healthy subjects. Diabet. Care. 1991;14:1057–1065
  4. Heinemann L, Kapitza C, Starke AAR, Heise T. Time-action profile of the insulin analogue B28Asp. Diabet. Med. 1996;13:683–684
  5. Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, et al. Insulin aspart (B28 Asp-insulin): a fast-acting analog of human insulin. Absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabet. Care. 1999;22:1501–1506
  6. Lindholm A, McEwen J, Riis A. Significantly improved postprandial glycaemic control with the novel rapid-acting insulin aspart. Diabetologia. 1998;41(Suppl. 1):49
  7. Jacobsen LV, Søgaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur. J. Clin. Pharmacol. 2000;56:399–403
  8. Weyer C, Heise T, Heineman L. Insulin aspart in a 70/30 premixed formulation: pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabet. Care. 1997;20:1612–1614
  9. Hermansen K, Colombo M, Storgaard H, Ostergaaed A, Kolendorf K, Madsbad S. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabet. Care. 2002;25:883–888
  10. Kapitza C, Nosek L, Lindholm A, Leth G, Codony SG, Heise T. Biphasic insulin aspart provides good metabolic control even when injected postprandially. Diabetes. 2001;50(Suppl. 2):A119; (Abstract 475-P)
  11. Declaration of Helsinki, Recommendations guiding medical physicians in biomedical research involving human subjects, JAMA 277 (1997) 925–926.

☆ The results of this study have been presented in poster form at the 2002 European Association for the Study of Diabetes (EASD) meeting in Budapest, Hungary (Warren et al., Postprandial dosing of NovoLog® Mix 70/30 in elderly subjects with type 2 diabetes, Diabetologia 2002, V45 Suppl. 2, A254, abstract 790).

PII: S0168-8227(04)00054-3

doi: 10.1016/j.diabres.2004.02.010

Diabetes Research and Clinical Practice
Volume 66, Issue 1 , Pages 23-29 , October 2004

Article Tools

* Image Usage & Resolution